Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Reyataz

REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 55–56

HOS-112195 · Präparat HOS-093615

55 Medicinal products by Interaction Recommendations therapeutic area concerning co-administration Verapamil Serum concentrations of verapamil may be Caution should be exercised increased by REYATAZ due to CYP3A4 when verapamil is co- inhibition. administered with REYATAZ. CORTICOSTEROIDS Dexamethasone and other Co-administration with dexamethasone or Co-administration with corticosteroids (all routes of other corticosteroids that induce CYP3A corticosteroids (all routes of administration) may result in loss of therapeutic effect of administration) that are REYATAZ and development of resistance metabolised by CYP3A, to atazanavir and/or ritonavir. Alternative particularly for long-term use, corticosteroids should be considered. may increase the risk for development of systemic The mechanism of interaction is CYP3A4 corticosteroid effects including induction by dexamethasone and CYP3A4 Cushing’s syndrome and inhibition by atazanavir and/or ritonavir. adrenal suppression. The potential benefit of treatment versus the risk of systemic corticosteroid effects should be considered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dexamethasone (HOS-084535) ritonavir (HOS-084521) verapamil (HOS-090602)